Published in Oncoimmunology on January 07, 2015
Signal transducer and activator of transcription 3 in myeloid-derived suppressor cells: an opportunity for cancer therapy. Oncotarget (2016) 0.79
A rationally designed combined treatment with an alphavirus-based cancer vaccine, sunitinib and low-dose tumor irradiation completely blocks tumor development. Oncoimmunology (2015) 0.79
Immunostimulatory Gene Therapy Using Oncolytic Viruses as Vehicles. Viruses (2015) 0.77
Clinical and kinomic analysis identifies peripheral blood mononuclear cells as a potential pharmacodynamic biomarker in metastatic renal cell carcinoma patients treated with sunitinib. Oncotarget (2016) 0.76
Pro-Tumoral Inflammatory Myeloid Cells as Emerging Therapeutic Targets. Int J Mol Sci (2016) 0.76
Folate-Hapten Mediated Immunotherapy Synergizes with Vascular Endothelial Growth Factor Receptor Inhibitors in Treating Murine Models of Cancer. Mol Cancer Ther (2016) 0.75
Detection of inflammatory cell function using (13)C magnetic resonance spectroscopy of hyperpolarized [6-(13)C]-arginine. Sci Rep (2016) 0.75
GM-CSF signalling blockade and chemotherapeutic agents act in concert to inhibit the function of myeloid-derived suppressor cells in vitro. Clin Transl Immunology (2016) 0.75
Sunitinib: the antiangiogenic effects and beyond. Onco Targets Ther (2016) 0.75
Tumor-targeted delivery of sunitinib base enhances vaccine therapy for advanced melanoma by remodeling the tumor microenvironment. J Control Release (2016) 0.75
Adjunct Strategies for Tuberculosis Vaccines: Modulating Key Immune Cell Regulatory Mechanisms to Potentiate Vaccination. Front Immunol (2016) 0.75
Combination strategies to enhance the potency of monocyte-derived dendritic cell-based cancer vaccines. Immunotherapy (2016) 0.75
Chemotherapeutic agent-mediated elimination of myeloid-derived suppressor cells. Oncoimmunology (2017) 0.75
Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods (2001) 414.27
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med (2007) 39.39
Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol (2009) 25.96
Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol (2012) 12.19
Sunitinib in patients with metastatic renal cell carcinoma. JAMA (2006) 11.33
In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res (2003) 9.92
Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol (2001) 7.43
Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol (2005) 7.12
Altered macrophage differentiation and immune dysfunction in tumor development. J Clin Invest (2007) 6.31
Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res (1996) 6.03
Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin Cancer Res (2005) 5.16
Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res (2009) 5.10
Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells. J Exp Med (2004) 4.77
Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor. J Immunol (2005) 4.18
Targeting the cancer kinome through polypharmacology. Nat Rev Cancer (2010) 3.74
The secret ally: immunostimulation by anticancer drugs. Nat Rev Drug Discov (2012) 3.60
Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells. Cancer Res (2008) 3.57
Characterization of cytokine-induced myeloid-derived suppressor cells from normal human peripheral blood mononuclear cells. J Immunol (2010) 3.38
Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice. J Clin Invest (2008) 3.37
The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. Cancer Res (2009) 3.18
Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells. Cancer Res (2009) 3.07
Myeloid-derived suppressor cells suppress antitumor immune responses through IDO expression and correlate with lymph node metastasis in patients with breast cancer. J Immunol (2013) 2.96
Reversion of immune tolerance in advanced malignancy: modulation of myeloid-derived suppressor cell development by blockade of stem-cell factor function. Blood (2007) 2.65
Tumor-induced immune dysfunctions caused by myeloid suppressor cells. J Immunother (2001) 2.25
Monocytic CCR2(+) myeloid-derived suppressor cells promote immune escape by limiting activated CD8 T-cell infiltration into the tumor microenvironment. Cancer Res (2011) 2.20
Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses. Blood (2008) 2.09
Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained. Cancer Res (2010) 1.92
Antiangiogenic and anti-invasive effects of sunitinib on experimental human glioblastoma. Neuro Oncol (2007) 1.73
Myeloid suppressor cell depletion augments antitumor activity in lung cancer. PLoS One (2012) 1.70
Arginases I and II: do their functions overlap? Mol Genet Metab (2004) 1.67
Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248. Mol Cancer Ther (2006) 1.64
MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy. Int Immunopharmacol (2011) 1.51
Therapeutic regulation of myeloid-derived suppressor cells and immune response to cancer vaccine in patients with extensive stage small cell lung cancer. Cancer Immunol Immunother (2013) 1.43
Doxorubicin eliminates myeloid-derived suppressor cells and enhances the efficacy of adoptive T-cell transfer in breast cancer. Cancer Res (2013) 1.42
Consequence of dose scheduling of sunitinib on host immune response elements and vaccine combination therapy. Int J Cancer (2011) 1.34
Control of the immune response by pro-angiogenic factors. Front Oncol (2014) 1.26
S100A7 enhances mammary tumorigenesis through upregulation of inflammatory pathways. Cancer Res (2011) 1.25
Kinase inhibitor Sorafenib modulates immunosuppressive cell populations in a murine liver cancer model. Lab Invest (2011) 1.22
Gr-1 antibody induces STAT signaling, macrophage marker expression and abrogation of myeloid-derived suppressor cell activity in BM cells. Eur J Immunol (2009) 1.22
Expression of NADPH oxidase homologues and accessory genes in human cancer cell lines, tumours and adjacent normal tissues. Free Radic Res (2009) 1.16
Myeloid-derived suppressor cells interact with tumors in terms of myelopoiesis, tumorigenesis and immunosuppression: thick as thieves. J Cancer (2012) 1.12
Molecular basis and management of gastrointestinal stromal tumors. World J Gastroenterol (2010) 1.07
c-Kit-targeting immunotherapy for hereditary melanoma in a mouse model. Cancer Res (2004) 1.04
Blocking programmed death-1 ligand-PD-1 interactions by local gene therapy results in enhancement of antitumor effect of secondary lymphoid tissue chemokine. J Immunol (2004) 1.01
Long-term response to sunitinib therapy for metastatic renal cell carcinoma. Clin Genitourin Cancer (2013) 1.00
iNOS-selective inhibitors for cancer prevention: promise and progress. Future Med Chem (2012) 0.96
Superior therapeutic efficacy of alphavirus-mediated immunization against human papilloma virus type 16 antigens in a murine tumour model: effects of the route of immunization. Antivir Ther (2004) 0.91
Systemic treatment options for untreated patients with metastatic clear cell renal cancer. Semin Oncol (2013) 0.90
CD4+PD-1+ T cells acting as regulatory cells during the induction of anterior chamber-associated immune deviation. Invest Ophthalmol Vis Sci (2006) 0.89
CD69 expression as an index of T-cell function: assay standardization, validation and use in monitoring immune recovery. Cytotherapy (2007) 0.89
In Vitro and In Vivo Analysis of RTK Inhibitor Efficacy and Identification of Its Novel Targets in Glioblastomas. Transl Oncol (2013) 0.89
Therapeutic immunization and local low-dose tumor irradiation, a reinforcing combination. Int J Cancer (2013) 0.89
Blockade of NFκB activity by Sunitinib increases cell death in Bortezomib-treated endometrial carcinoma cells. Mol Oncol (2012) 0.88
Combination of sunitinib with anti-tumor vaccination inhibits T cell priming and requires careful scheduling to achieve productive immunotherapy. Int J Cancer (2013) 0.87
A comparative study on the immunotherapeutic efficacy of recombinant Semliki Forest virus and adenovirus vector systems in a murine model for cervical cancer. Gene Ther (2007) 0.85
Arginase 2 and nitric oxide synthase: Pathways associated with the pathogenesis of thyroid tumors. Free Radic Biol Med (2010) 0.85
Immunological effects of multikinase inhibitors for kidney cancer: a clue for integration with cellular therapies? J Cancer (2011) 0.84
Role of regulatory T-cells in immunization strategies involving a recombinant alphavirus vector system. Antivir Ther (2011) 0.84
The effect of the anti-angiogenic drug sunitinib malate on the vascular architecture of oral squamous cell carcinoma. Microsc Res Tech (2014) 0.77
Role of T cell competition in the induction of cytotoxic T lymphocyte activity during viral vector-based immunization regimens. Vaccine (2010) 0.77